Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | DHODH | Q02127 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.39 |
| ▸ | FBP1 | P09467 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079966 | 0.87 | KMT2A (0.40) | MEN1KMT2APIN1MAPTAPP | |
| SCHEMBL6079453 | 0.84 | MAPT (0.43) | MEN1KMT2AMAPT | |
| SCHEMBL6080726 | 0.83 | KMT2A (0.41) | MEN1KMT2APIN1MAPTAPP | |
| SCHEMBL6081200 | 0.80 | ALDH1A1 (0.46) | MEN1KMT2AMAPT | |
| SCHEMBL6594141 | 0.80 | CYP19A1 (0.47) | MEN1KMT2ADHODHCYP19A1CYP11B1 | |
| SCHEMBL6594148 | 0.80 | CYP19A1 (0.47) | MEN1KMT2ADHODHCYP19A1CYP11B1 | |
| Benzene SCHEMBL6080664 | 0.77 | MAPT (0.39) | MEN1KMT2APIN1MAPTAPP | |
| SCHEMBL6080724 | 0.76 | MAPT (0.38) | MEN1KMT2ADHODHPIN1MAPT | |
| SCHEMBL6080118 | 0.76 | CTSV (0.40) | MEN1KMT2ACYP19A1PIN1MAPT | |
| SCHEMBL6079324 | 0.76 | CTSV (0.40) | MEN1KMT2ACYP19A1PIN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | MEN1 740/4885KMT2A 1384/4885DHODH 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.